S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Brickell Biotech (BBI) Stock Forecast, Price & News

-0.01 (-5.26%)
(As of 05/17/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
2.71 million shs
Average Volume
7.82 million shs
Market Capitalization
$21.49 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BBI News and Ratings via Email

Sign-up to receive the latest news and ratings for Brickell Biotech and its competitors with MarketBeat's FREE daily newsletter.

Brickell Biotech logo

About Brickell Biotech

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.


Brickell Biotech Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$400 thousand
Book Value
$0.22 per share


Net Income
$-39.47 million
Net Margins
Pretax Margin




Free Float
Market Cap
$21.49 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.50 out of 5 stars

Medical Sector

1037th out of 1,426 stocks

Biological Products, Except Diagnostic Industry

161st out of 210 stocks

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Brickell Biotech (NASDAQ:BBI) Frequently Asked Questions

Is Brickell Biotech a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Brickell Biotech in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Brickell Biotech stock.
View analyst ratings for Brickell Biotech
or view top-rated stocks.

Are investors shorting Brickell Biotech?

Brickell Biotech saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 4,210,000 shares, an increase of 66.4% from the April 15th total of 2,530,000 shares. Based on an average daily volume of 5,300,000 shares, the days-to-cover ratio is currently 0.8 days.
View Brickell Biotech's Short Interest

When is Brickell Biotech's next earnings date?

Brickell Biotech is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Brickell Biotech

How were Brickell Biotech's earnings last quarter?

Brickell Biotech, Inc. (NASDAQ:BBI) released its quarterly earnings results on Thursday, May, 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.02. Brickell Biotech had a negative net margin of 8,325.47% and a negative trailing twelve-month return on equity of 191.55%. During the same period in the previous year, the firm earned ($0.15) EPS.
View Brickell Biotech's earnings history

What price target have analysts set for BBI?

3 analysts have issued 12-month price targets for Brickell Biotech's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Brickell Biotech's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 1,011.1% from the stock's current price.
View analysts' price targets for Brickell Biotech
or view top-rated stocks among Wall Street analysts.

Who are Brickell Biotech's key executives?
Brickell Biotech's management team includes the following people:
What other stocks do shareholders of Brickell Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brickell Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (vbiv), Jaguar Health (JAGX), Miragen Therapeutics (MGEN), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Amarin (AMRN), Fortress Biotech (FBIO) and iBio (IBIO).

What is Brickell Biotech's stock symbol?

Brickell Biotech trades on the NASDAQ under the ticker symbol "BBI."

Who are Brickell Biotech's major shareholders?

Brickell Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.61%), Renaissance Technologies LLC (1.19%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Brickell Biotech stock include Andrew D Sklawer, David R Mcavoy, David R Mcavoy, Deepak Chadha, Dennison T Veru, Reginald L Hardy, Reginald L Hardy and Robert Busard Brown.
View institutional ownership trends for Brickell Biotech

Which major investors are selling Brickell Biotech stock?

BBI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Brickell Biotech
or view top insider-selling stocks.

Which major investors are buying Brickell Biotech stock?

BBI stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Brickell Biotech stock in the last two years include Andrew D Sklawer, David R Mcavoy, Deepak Chadha, Dennison T Veru, Reginald L Hardy, and Robert Busard Brown.
View insider buying and selling activity for Brickell Biotech
or or view top insider-buying stocks.

How do I buy shares of Brickell Biotech?

Shares of BBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brickell Biotech's stock price today?

One share of BBI stock can currently be purchased for approximately $0.18.

How much money does Brickell Biotech make?

Brickell Biotech has a market capitalization of $21.49 million and generates $400 thousand in revenue each year. The company earns $-39.47 million in net income (profit) each year or ($0.460010) on an earnings per share basis.

How many employees does Brickell Biotech have?

Brickell Biotech employs 16 workers across the globe.

What is Brickell Biotech's official website?

The official website for Brickell Biotech is www.brickellbio.com.

How can I contact Brickell Biotech?

Brickell Biotech's mailing address is 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301. The company can be reached via phone at (720) 505-4755, via email at [email protected], or via fax at 858-646-1150.

This page was last updated on 5/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.